Gastrointestinal Drugs Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2029
4.3%
CAGR (2022-2029)
261.95 USD Bn.
Market Size
325
Report Pages
154
Market Tables
Overview
Gastrointestinal Drugs Market size is expected to reach US$ 366.85 Bn. by year 2029 at a CAGR of 4.3% during the forecast period.
Gastrointestinal drugs including promotility drugs, antimotility drugs, and drugs for acid-related disorders. The commonly used gastrointestinal drugs as a group are considered safe and are generally used. A range of neurologic complications is performed successive use of various gastrointestinal drugs.
To know about the Research Methodology :- Request Free Sample Report
Increasing prevalence of gastrointestinal disease universal and rising awareness and government initiatives are expected driving factors in the global gastrointestinal drugs market. Moreover, emerging generic drugs owing to its cost-effectiveness and the rising popularity of diseases such as irritable bowel syndrome are expected to be major factors attributed to the growth of the global market.
However, the side effects associated with the drugs is restraint in the market. Rising investments in research and development activities for the innovation of novel drugs and the technological developments in the treatment process are major opportunities in the market.
Based on the drug category, the anti-inflammatory drug segment is dominated by xx% market share in the forecast period. The anti-inflammatory drug segment is used to treat situations like arthritis, chronic obstructive pulmonary disease, and other diseases. Anti-inflammatory drugs are a growing incidence of these viruses is the main cause of improving the segment upwards.
Gastroesophageal reflux disorder segment is expected to dominate the xx% market share during the forecast period. Owing to the increase in awareness between physicians and patients about the side effects of the proton pump inhibitors class of drugs. Gastroesophageal reflux disease is a chronic gastric disorder that happens because of problems arising in the esophagus. Gastroesophageal reflux disease is a chronic and highly prevalent medical problem during the forecast period.
Regionally, Asia Pacific is expected to account for the largest share of the gastrointestinal drug market during the forecast period. The development of the healthcare and medical infrastructure increase in public and private investments for technological advancements and life sciences research. The treatments and medicinal processes of gastrointestinal syndromes or diseases in future economies, such as China and India, are estimated to fuel the global gastrointestinal drug market during the forecast period.
The objective of the report is to present comprehensive analysis of global gastrointestinal drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding global gastrointestinal drugs market dynamics, structure by analyzing the market segments, and project the global gastrointestinal drugs market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global gastrointestinal drugs market make the report investor’s guide.
Scope of the Global Gastrointestinal Drugs Market: Inquire before buying
| Global Gastrointestinal Drugs Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2021 | Forecast Period: | 2022-2029 |
| Historical Data: | 2017 to 2021 | Market Size in 2021: | US $ 261.95 Bn. |
| Forecast Period 2022 to 2029 CAGR: | 4.3% | Market Size in 2029: | US $ 366.85 Bn. |
| Segments Covered: | by Drug Category | • Acid Neutralizers o Antacids o H2 Antagonists o Proton Pump Inhibitors • Helicobacter Pylori Eradication • Laxatives and Anti-diarrheal • Antiemetic and Antinauseants • Anti-inflammatory Drugs • Biologics • Others |
|
| by Route of Administration | • Oral • Parenteral • Rectal |
||
| by Disease Type | •Gastroesophageal Reflux Disorder • Irritable Bowel Syndrome • Others |
||
| by End-User | • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies |
||
Gastrointestinal Drugs Market, by Region
• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America
Gastrointestinal Drugs Market Key Players are:
• AbbVie Inc.
• AstraZeneca
• Johnson & Johnson
• Abbott Laboratories
• Allergan Plc
• Bayer AG
• Janssen Biotech Inc.
• Takeda Pharmaceutical Company Limited
• Eisai Co.Ltd.
• Valeant Pharmaceuticals
• Sanofi
• Janssen Biotech
• GlaxoSmithKline Plc
• Boehringer Ingelheim GmbH
• Novo Nordisk A/S
• Teva
• Zeria
• Perrigo
• Purdue Pharma
• C.B. Fleet
Frequently Asked questions
1. What is the market size of the Global Gastrointestinal Drugs Market in 2021?
Ans. The market size Global Gastrointestinal Drugs Market in 2021 was US$ 261.95 Billion.
2. What are the different segments of the Global Gastrointestinal Drugs Market?
Ans. The Global Gastrointestinal Drugs Market is divided into Disease Type, Drug Category , Route of Administration and End-User.
3. What is the study period of this market?
Ans. The Global Gastrointestinal Drugs Market will be studied from 2021 to 2029.
4. Which region is expected to hold the highest Global Gastrointestinal Drugs Market share?
Ans. The Asia Pacific dominates the market share in the market.
5. What is the Forecast Period of Global Gastrointestinal Drugs Market?
Ans. The Forecast Period of the market is 2022-2029 in the market.
Table of Contents
Global Gastrointestinal Drugs Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Gastrointestinal Drugs Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Gastrointestinal Drugs Market Analysis and Forecast
6.1. Global Gastrointestinal Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Gastrointestinal Drugs Market Analysis and Forecast, by Drug Category
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
7.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Drug Category
7.5. Global Gastrointestinal Drugs Market Analysis, by Drug Category
7.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Category
8. Global Gastrointestinal Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
8.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Route of Administration
8.5. Global Gastrointestinal Drugs Market Analysis, by Route of Administration
8.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration
9. Global Gastrointestinal Drugs Market Analysis and Forecast, by Disease Type
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
9.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Disease Type
9.5. Global Gastrointestinal Drugs Market Analysis, by Disease Type
9.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disease Type
10. Global Gastrointestinal Drugs Market Analysis and Forecast, by End-Users
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Gastrointestinal Drugs Market Value Share Analysis, by End-Users
10.4. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by End-Users
10.5. Global Gastrointestinal Drugs Market Analysis, by End-Users
10.6. Global Gastrointestinal Drugs Market Attractiveness Analysis, by End-Users
11. Global Gastrointestinal Drugs Market Analysis, by Region
11.1. Global Gastrointestinal Drugs Market Value Share Analysis, by Region
11.2. Global Gastrointestinal Drugs Market Size (US$ Bn) Forecast, by Region
11.3. Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region
12. North America Gastrointestinal Drugs Market Analysis
12.1. Key Findings
12.2. North America Gastrointestinal Drugs Market Overview
12.3. North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
12.4. North America Gastrointestinal Drugs Market Forecast, by Drug Category
12.4.1. Acid Neutralizers
12.4.1.1. Antacids
12.4.1.2. H2 Antagonists
12.4.1.3. Proton Pump Inhibitors
12.4.2. Helicobacter Pylori Eradication
12.4.3. Laxatives and Anti-diarrheal
12.4.4. Antiemetic and Antinauseants
12.4.5. Anti-inflammatory Drugs
12.4.6. Biologics
12.4.7. Others
12.5. North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
12.6. North America Gastrointestinal Drugs Market Forecast, by Route of Administration
12.6.1. Oral
12.6.2. Parenteral
12.6.3. Rectal
12.7. North America Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
12.8. North America Gastrointestinal Drugs Market Forecast, by Disease Type
12.8.1. Gastroesophageal Reflux Disorder
12.8.2. Irritable Bowel Syndrome
12.8.3. Others
12.9. North America Gastrointestinal Drugs Market Value Share Analysis, by End-Users
12.10. North America Gastrointestinal Drugs Market Forecast, by End-Users
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. North America Gastrointestinal Drugs Market Value Share Analysis, by Country
12.12. North America Gastrointestinal Drugs Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Gastrointestinal Drugs Market Analysis, by Country
12.14. U.S. Gastrointestinal Drugs Market Forecast, by Drug Category
12.14.1. Acid Neutralizers
12.14.1.1. Antacids
12.14.1.2. H2 Antagonists
12.14.1.3. Proton Pump Inhibitors
12.14.2. Helicobacter Pylori Eradication
12.14.3. Laxatives and Anti-diarrheal
12.14.4. Antiemetic and Antinauseants
12.14.5. Anti-inflammatory Drugs
12.14.6. Biologics
12.14.7. Others
12.15. U.S. Gastrointestinal Drugs Market Forecast, by Route of Administration
12.15.1. Oral
12.15.2. Parenteral
12.15.3. Rectal
12.16. U.S. Gastrointestinal Drugs Market Forecast, by Disease Type
12.16.1. Gastroesophageal Reflux Disorder
12.16.2. Irritable Bowel Syndrome
12.16.3. Others
12.17. U.S. Gastrointestinal Drugs Market Forecast, by End-Users
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Online Pharmacies
12.18. Canada Gastrointestinal Drugs Market Forecast, by Drug Category
12.18.1. Acid Neutralizers
12.18.1.1. Antacids
12.18.1.2. H2 Antagonists
12.18.1.3. Proton Pump Inhibitors
12.18.2. Helicobacter Pylori Eradication
12.18.3. Laxatives and Anti-diarrheal
12.18.4. Antiemetic and Antinauseants
12.18.5. Anti-inflammatory Drugs
12.18.6. Biologics
12.18.7. Others
12.19. Canada Gastrointestinal Drugs Market Forecast, by Route of Administration
12.19.1. Oral
12.19.2. Parenteral
12.19.3. Rectal
12.20. Canada Gastrointestinal Drugs Market Forecast, by Disease Type
12.20.1. Gastroesophageal Reflux Disorder
12.20.2. Irritable Bowel Syndrome
12.20.3. Others
12.21. Canada Gastrointestinal Drugs Market Forecast, by End-Users
12.21.1. Hospital Pharmacies
12.21.2. Retail Pharmacies
12.21.3. Online Pharmacies
12.22. North America Gastrointestinal Drugs Market Attractiveness Analysis
12.22.1. By Drug Category
12.22.2. By Route of Administration
12.22.3. By Disease Type
12.22.4. By End-Users
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments
13. Europe Gastrointestinal Drugs Market Analysis
13.1. Key Findings
13.2. Europe Gastrointestinal Drugs Market Overview
13.3. Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
13.4. Europe Gastrointestinal Drugs Market Forecast, by Drug Category
13.4.1. Acid Neutralizers
13.4.1.1. Antacids
13.4.1.2. H2 Antagonists
13.4.1.3. Proton Pump Inhibitors
13.4.2. Helicobacter Pylori Eradication
13.4.3. Laxatives and Anti-diarrheal
13.4.4. Antiemetic and Antinauseants
13.4.5. Anti-inflammatory Drugs
13.4.6. Biologics
13.4.7. Others
13.5. Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
13.6. Europe Gastrointestinal Drugs Market Forecast, by Route of Administration
13.6.1. Oral
13.6.2. Parenteral
13.6.3. Rectal
13.7. Europe Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
13.8. Europe Gastrointestinal Drugs Market Forecast, by Disease Type
13.8.1. Gastroesophageal Reflux Disorder
13.8.2. Irritable Bowel Syndrome
13.8.3. Others
13.9. Europe Gastrointestinal Drugs Market Value Share Analysis, by End-Users
13.10. Europe Gastrointestinal Drugs Market Forecast, by End-Users
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Europe Gastrointestinal Drugs Market Value Share Analysis, by Country
13.12. Europe Gastrointestinal Drugs Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Gastrointestinal Drugs Market Analysis, by Country
13.14. Germany Gastrointestinal Drugs Market Forecast, by Drug Category
13.14.1. Acid Neutralizers
13.14.1.1. Antacids
13.14.1.2. H2 Antagonists
13.14.1.3. Proton Pump Inhibitors
13.14.2. Helicobacter Pylori Eradication
13.14.3. Laxatives and Anti-diarrheal
13.14.4. Antiemetic and Antinauseants
13.14.5. Anti-inflammatory Drugs
13.14.6. Biologics
13.14.7. Others
13.15. Germany Gastrointestinal Drugs Market Forecast, by Route of Administration
13.15.1. Oral
13.15.2. Parenteral
13.15.3. Rectal
13.16. Germany Gastrointestinal Drugs Market Forecast, by Disease Type
13.16.1. Gastroesophageal Reflux Disorder
13.16.2. Irritable Bowel Syndrome
13.16.3. Others
13.17. Germany Gastrointestinal Drugs Market Forecast, by End-Users
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Online Pharmacies
13.18. U.K. Gastrointestinal Drugs Market Forecast, by Drug Category
13.18.1. Acid Neutralizers
13.18.1.1. Antacids
13.18.1.2. H2 Antagonists
13.18.1.3. Proton Pump Inhibitors
13.18.2. Helicobacter Pylori Eradication
13.18.3. Laxatives and Anti-diarrheal
13.18.4. Antiemetic and Antinauseants
13.18.5. Anti-inflammatory Drugs
13.18.6. Biologics
13.18.7. Others
13.19. U.K. Gastrointestinal Drugs Market Forecast, by Route of Administration
13.19.1. Oral
13.19.2. Parenteral
13.19.3. Rectal
13.20. U.K. Gastrointestinal Drugs Market Forecast, by Disease Type
13.20.1. Gastroesophageal Reflux Disorder
13.20.2. Irritable Bowel Syndrome
13.20.3. Others
13.21. U.K. Gastrointestinal Drugs Market Forecast, by End-Users
13.21.1. Hospital Pharmacies
13.21.2. Retail Pharmacies
13.21.3. Online Pharmacies
13.22. France Gastrointestinal Drugs Market Forecast, by Drug Category
13.22.1. Acid Neutralizers
13.22.1.1. Antacids
13.22.1.2. H2 Antagonists
13.22.1.3. Proton Pump Inhibitors
13.22.2. Helicobacter Pylori Eradication
13.22.3. Laxatives and Anti-diarrheal
13.22.4. Antiemetic and Antinauseants
13.22.5. Anti-inflammatory Drugs
13.22.6. Biologics
13.22.7. Others
13.23. France Gastrointestinal Drugs Market Forecast, by Route of Administration
13.23.1. Oral
13.23.2. Parenteral
13.23.3. Rectal
13.24. France Gastrointestinal Drugs Market Forecast, by Disease Type
13.24.1. Gastroesophageal Reflux Disorder
13.24.2. Irritable Bowel Syndrome
13.24.3. Others
13.25. France Gastrointestinal Drugs Market Forecast, by End-Users
13.25.1. Hospital Pharmacies
13.25.2. Retail Pharmacies
13.25.3. Online Pharmacies
13.26. Italy Gastrointestinal Drugs Market Forecast, by Drug Category
13.26.1. Acid Neutralizers
13.26.1.1. Antacids
13.26.1.2. H2 Antagonists
13.26.1.3. Proton Pump Inhibitors
13.26.2. Helicobacter Pylori Eradication
13.26.3. Laxatives and Anti-diarrheal
13.26.4. Antiemetic and Antinauseants
13.26.5. Anti-inflammatory Drugs
13.26.6. Biologics
13.26.7. Others
13.27. Italy Gastrointestinal Drugs Market Forecast, by Route of Administration
13.27.1. Oral
13.27.2. Parenteral
13.27.3. Rectal
13.28. Italy Gastrointestinal Drugs Market Forecast, by Disease Type
13.28.1. Gastroesophageal Reflux Disorder
13.28.2. Irritable Bowel Syndrome
13.28.3. Others
13.29. Italy Gastrointestinal Drugs Market Forecast, by End-Users
13.29.1. Hospital Pharmacies
13.29.2. Retail Pharmacies
13.29.3. Online Pharmacies
13.30. Spain Gastrointestinal Drugs Market Forecast, by Drug Category
13.30.1. Acid Neutralizers
13.30.1.1. Antacids
13.30.1.2. H2 Antagonists
13.30.1.3. Proton Pump Inhibitors
13.30.2. Helicobacter Pylori Eradication
13.30.3. Laxatives and Anti-diarrheal
13.30.4. Antiemetic and Antinauseants
13.30.5. Anti-inflammatory Drugs
13.30.6. Biologics
13.30.7. Others
13.31. Spain Gastrointestinal Drugs Market Forecast, by Route of Administration
13.31.1. Oral
13.31.2. Parenteral
13.31.3. Rectal
13.32. Spain Gastrointestinal Drugs Market Forecast, by Disease Type
13.32.1. Gastroesophageal Reflux Disorder
13.32.2. Irritable Bowel Syndrome
13.32.3. Others
13.33. Spain Gastrointestinal Drugs Market Forecast, by End-Users
13.33.1. Hospital Pharmacies
13.33.2. Retail Pharmacies
13.33.3. Online Pharmacies
13.34. Rest of Europe Gastrointestinal Drugs Market Forecast, by Drug Category
13.34.1. Acid Neutralizers
13.34.1.1. Antacids
13.34.1.2. H2 Antagonists
13.34.1.3. Proton Pump Inhibitors
13.34.2. Helicobacter Pylori Eradication
13.34.3. Laxatives and Anti-diarrheal
13.34.4. Antiemetic and Antinauseants
13.34.5. Anti-inflammatory Drugs
13.34.6. Biologics
13.34.7. Others
13.35. Rest of Europe Gastrointestinal Drugs Market Forecast, by Route of Administration
13.35.1. Oral
13.35.2. Parenteral
13.35.3. Rectal
13.36. Rest of Europe Gastrointestinal Drugs Market Forecast, by Disease Type
13.36.1. Gastroesophageal Reflux Disorder
13.36.2. Irritable Bowel Syndrome
13.36.3. Others
13.37. Rest Of Europe Gastrointestinal Drugs Market Forecast, by End-Users
13.37.1. Hospital Pharmacies
13.37.2. Retail Pharmacies
13.37.3. Online Pharmacies
13.38. Europe Gastrointestinal Drugs Market Attractiveness Analysis
13.38.1. By Drug Category
13.38.2. By Route of Administration
13.38.3. By Disease Type
13.38.4. By End-Users
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments
14. Asia Pacific Gastrointestinal Drugs Market Analysis
14.1. Key Findings
14.2. Asia Pacific Gastrointestinal Drugs Market Overview
14.3. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
14.4. Asia Pacific Gastrointestinal Drugs Market Forecast, by Drug Category
14.4.1. Acid Neutralizers
14.4.1.1. Antacids
14.4.1.2. H2 Antagonists
14.4.1.3. Proton Pump Inhibitors
14.4.2. Helicobacter Pylori Eradication
14.4.3. Laxatives and Anti-diarrheal
14.4.4. Antiemetic and Antinauseants
14.4.5. Anti-inflammatory Drugs
14.4.6. Biologics
14.4.7. Others
14.5. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
14.6. Asia Pacific Gastrointestinal Drugs Market Forecast, by Route of Administration
14.6.1. Oral
14.6.2. Parenteral
14.6.3. Rectal
14.7. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
14.8. Asia Pacific Gastrointestinal Drugs Market Forecast, by Disease Type
14.8.1. Gastroesophageal Reflux Disorder
14.8.2. Irritable Bowel Syndrome
14.8.3. Others
14.9. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by End-Users
14.10. Asia Pacific Gastrointestinal Drugs Market Forecast, by End-Users
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country
14.12. Asia Pacific Gastrointestinal Drugs Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Gastrointestinal Drugs Market Analysis, by Country
14.14. China Gastrointestinal Drugs Market Forecast, by Drug Category
14.14.1. Acid Neutralizers
14.14.1.1. Antacids
14.14.1.2. H2 Antagonists
14.14.1.3. Proton Pump Inhibitors
14.14.2. Helicobacter Pylori Eradication
14.14.3. Laxatives and Anti-diarrheal
14.14.4. Antiemetic and Antinauseants
14.14.5. Anti-inflammatory Drugs
14.14.6. Biologics
14.14.7. Others
14.15. China Gastrointestinal Drugs Market Forecast, by Route of Administration
14.15.1. Oral
14.15.2. Parenteral
14.15.3. Rectal
14.16. China Gastrointestinal Drugs Market Forecast, by Disease Type
14.16.1. Gastroesophageal Reflux Disorder
14.16.2. Irritable Bowel Syndrome
14.16.3. Others
14.17. China Gastrointestinal Drugs Market Forecast, by End-Users
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Online Pharmacies
14.18. India Gastrointestinal Drugs Market Forecast, by Drug Category
14.18.1. Acid Neutralizers
14.18.1.1. Antacids
14.18.1.2. H2 Antagonists
14.18.1.3. Proton Pump Inhibitors
14.18.2. Helicobacter Pylori Eradication
14.18.3. Laxatives and Anti-diarrheal
14.18.4. Antiemetic and Antinauseants
14.18.5. Anti-inflammatory Drugs
14.18.6. Biologics
14.18.7. Others
14.19. India Gastrointestinal Drugs Market Forecast, by Route of Administration
14.19.1. Oral
14.19.2. Parenteral
14.19.3. Rectal
14.20. India Gastrointestinal Drugs Market Forecast, by Disease Type
14.20.1. Gastroesophageal Reflux Disorder
14.20.2. Irritable Bowel Syndrome
14.20.3. Others
14.21. India Gastrointestinal Drugs Market Forecast, by End-Users
14.21.1. Hospital Pharmacies
14.21.2. Retail Pharmacies
14.21.3. Online Pharmacies
14.22. Japan Gastrointestinal Drugs Market Forecast, by Drug Category
14.22.1. Acid Neutralizers
14.22.1.1. Antacids
14.22.1.2. H2 Antagonists
14.22.1.3. Proton Pump Inhibitors
14.22.2. Helicobacter Pylori Eradication
14.22.3. Laxatives and Anti-diarrheal
14.22.4. Antiemetic and Antinauseants
14.22.5. Anti-inflammatory Drugs
14.22.6. Biologics
14.22.7. Others
14.23. Japan Gastrointestinal Drugs Market Forecast, by Route of Administration
14.23.1. Oral
14.23.2. Parenteral
14.23.3. Rectal
14.24. Japan Gastrointestinal Drugs Market Forecast, by Disease Type
14.24.1. Gastroesophageal Reflux Disorder
14.24.2. Irritable Bowel Syndrome
14.24.3. Others
14.25. Japan Gastrointestinal Drugs Market Forecast, by End-Users
14.25.1. Hospital Pharmacies
14.25.2. Retail Pharmacies
14.25.3. Online Pharmacies
14.26. ASEAN Gastrointestinal Drugs Market Forecast, by Drug Category
14.26.1. Acid Neutralizers
14.26.1.1. Antacids
14.26.1.2. H2 Antagonists
14.26.1.3. Proton Pump Inhibitors
14.26.2. Helicobacter Pylori Eradication
14.26.3. Laxatives and Anti-diarrheal
14.26.4. Antiemetic and Antinauseants
14.26.5. Anti-inflammatory Drugs
14.26.6. Biologics
14.26.7. Others
14.27. ASEAN Gastrointestinal Drugs Market Forecast, by Route of Administration
14.27.1. Oral
14.27.2. Parenteral
14.27.3. Rectal
14.28. ASEAN Gastrointestinal Drugs Market Forecast, by Disease Type
14.28.1. Gastroesophageal Reflux Disorder
14.28.2. Irritable Bowel Syndrome
14.28.3. Others
14.29. ASEAN Gastrointestinal Drugs Market Forecast, by End-Users
14.29.1. Hospital Pharmacies
14.29.2. Retail Pharmacies
14.29.3. Online Pharmacies
14.30. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Drug Category
14.30.1. Acid Neutralizers
14.30.1.1. Antacids
14.30.1.2. H2 Antagonists
14.30.1.3. Proton Pump Inhibitors
14.30.2. Helicobacter Pylori Eradication
14.30.3. Laxatives and Anti-diarrheal
14.30.4. Antiemetic and Antinauseants
14.30.5. Anti-inflammatory Drugs
14.30.6. Biologics
14.30.7. Others
14.31. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Route of Administration
14.31.1. Oral
14.31.2. Parenteral
14.31.3. Rectal
14.32. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by Disease Type
14.32.1. Gastroesophageal Reflux Disorder
14.32.2. Irritable Bowel Syndrome
14.32.3. Others
14.33. Rest of Asia Pacific Gastrointestinal Drugs Market Forecast, by End-Users
14.33.1. Hospital Pharmacies
14.33.2. Retail Pharmacies
14.33.3. Online Pharmacies
14.34. Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis
14.34.1. By Drug Category
14.34.2. By Route of Administration
14.34.3. By Disease Type
14.34.4. By End-Users
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments
15. Middle East & Africa Gastrointestinal Drugs Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Gastrointestinal Drugs Market Overview
15.3. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
15.4. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Drug Category
15.4.1. Acid Neutralizers
15.4.1.1. Antacids
15.4.1.2. H2 Antagonists
15.4.1.3. Proton Pump Inhibitors
15.4.2. Helicobacter Pylori Eradication
15.4.3. Laxatives and Anti-diarrheal
15.4.4. Antiemetic and Antinauseants
15.4.5. Anti-inflammatory Drugs
15.4.6. Biologics
15.4.7. Others
15.5. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
15.6. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Route of Administration
15.6.1. Oral
15.6.2. Parenteral
15.6.3. Rectal
15.7. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
15.8. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Disease Type
15.8.1. Gastroesophageal Reflux Disorder
15.8.2. Irritable Bowel Syndrome
15.8.3. Others
15.9. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by End-Users
15.10. Middle East & Africa Gastrointestinal Drugs Market Forecast, by End-Users
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Online Pharmacies
15.11. Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country
15.12. Middle East & Africa Gastrointestinal Drugs Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Gastrointestinal Drugs Market Analysis, by Country
15.14. GCC Gastrointestinal Drugs Market Forecast, by Drug Category
15.14.1. Acid Neutralizers
15.14.1.1. Antacids
15.14.1.2. H2 Antagonists
15.14.1.3. Proton Pump Inhibitors
15.14.2. Helicobacter Pylori Eradication
15.14.3. Laxatives and Anti-diarrheal
15.14.4. Antiemetic and Antinauseants
15.14.5. Anti-inflammatory Drugs
15.14.6. Biologics
15.14.7. Others
15.15. GCC Gastrointestinal Drugs Market Forecast, by Route of Administration
15.15.1. Oral
15.15.2. Parenteral
15.15.3. Rectal
15.16. GCC Gastrointestinal Drugs Market Forecast, by Disease Type
15.16.1. Gastroesophageal Reflux Disorder
15.16.2. Irritable Bowel Syndrome
15.16.3. Others
15.17. GCC Gastrointestinal Drugs Market Forecast, by End-Users
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Online Pharmacies
15.18. South Africa Gastrointestinal Drugs Market Forecast, by Drug Category
15.18.1. Acid Neutralizers
15.18.1.1. Antacids
15.18.1.2. H2 Antagonists
15.18.1.3. Proton Pump Inhibitors
15.18.2. Helicobacter Pylori Eradication
15.18.3. Laxatives and Anti-diarrheal
15.18.4. Antiemetic and Antinauseants
15.18.5. Anti-inflammatory Drugs
15.18.6. Biologics
15.18.7. Others
15.19. South Africa Gastrointestinal Drugs Market Forecast, by Route of Administration
15.19.1. Oral
15.19.2. Parenteral
15.19.3. Rectal
15.20. South Africa Gastrointestinal Drugs Market Forecast, by Disease Type
15.20.1. Gastroesophageal Reflux Disorder
15.20.2. Irritable Bowel Syndrome
15.20.3. Others
15.21. South Africa Gastrointestinal Drugs Market Forecast, by End-Users
15.21.1. Hospital Pharmacies
15.21.2. Retail Pharmacies
15.21.3. Online Pharmacies
15.22. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Drug Category
15.22.1. Acid Neutralizers
15.22.1.1. Antacids
15.22.1.2. H2 Antagonists
15.22.1.3. Proton Pump Inhibitors
15.22.2. Helicobacter Pylori Eradication
15.22.3. Laxatives and Anti-diarrheal
15.22.4. Antiemetic and Antinauseants
15.22.5. Anti-inflammatory Drugs
15.22.6. Biologics
15.22.7. Others
15.23. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Route of Administration
15.23.1. Oral
15.23.2. Parenteral
15.23.3. Rectal
15.24. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by Disease Type
15.24.1. Gastroesophageal Reflux Disorder
15.24.2. Irritable Bowel Syndrome
15.24.3. Others
15.25. Rest of Middle East & Africa Gastrointestinal Drugs Market Forecast, by End-Users
15.25.1. Hospital Pharmacies
15.25.2. Retail Pharmacies
15.25.3. Online Pharmacies
15.26. Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis
15.26.1. By Drug Category
15.26.2. By Route of Administration
15.26.3. By Disease Type
15.26.4. By End-Users
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments
16. South America Gastrointestinal Drugs Market Analysis
16.1. Key Findings
16.2. South America Gastrointestinal Drugs Market Overview
16.3. South America Gastrointestinal Drugs Market Value Share Analysis, by Drug Category
16.4. South America Gastrointestinal Drugs Market Forecast, by Drug Category
16.4.1. Acid Neutralizers
16.4.1.1. Antacids
16.4.1.2. H2 Antagonists
16.4.1.3. Proton Pump Inhibitors
16.4.2. Helicobacter Pylori Eradication
16.4.3. Laxatives and Anti-diarrheal
16.4.4. Antiemetic and Antinauseants
16.4.5. Anti-inflammatory Drugs
16.4.6. Biologics
16.4.7. Others
16.5. South America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration
16.6. South America Gastrointestinal Drugs Market Forecast, by Route of Administration
16.6.1. Oral
16.6.2. Parenteral
16.6.3. Rectal
16.7. South America Gastrointestinal Drugs Market Value Share Analysis, by Disease Type
16.8. South America Gastrointestinal Drugs Market Forecast, by Disease Type
16.8.1. Gastroesophageal Reflux Disorder
16.8.2. Irritable Bowel Syndrome
16.8.3. Others
16.9. South America Gastrointestinal Drugs Market Value Share Analysis, by End-Users
16.10. South America Gastrointestinal Drugs Market Forecast, by End-Users
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Online Pharmacies
16.11. South America Gastrointestinal Drugs Market Value Share Analysis, by Country
16.12. South America Gastrointestinal Drugs Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Gastrointestinal Drugs Market Analysis, by Country
16.14. Brazil Gastrointestinal Drugs Market Forecast, by Drug Category
16.14.1. Acid Neutralizers
16.14.1.1. Antacids
16.14.1.2. H2 Antagonists
16.14.1.3. Proton Pump Inhibitors
16.14.2. Helicobacter Pylori Eradication
16.14.3. Laxatives and Anti-diarrheal
16.14.4. Antiemetic and Antinauseants
16.14.5. Anti-inflammatory Drugs
16.14.6. Biologics
16.14.7. Others
16.15. Brazil Gastrointestinal Drugs Market Forecast, by Route of Administration
16.15.1. Oral
16.15.2. Parenteral
16.15.3. Rectal
16.16. Brazil Gastrointestinal Drugs Market Forecast, by Disease Type
16.16.1. Gastroesophageal Reflux Disorder
16.16.2. Irritable Bowel Syndrome
16.16.3. Others
16.17. Brazil Gastrointestinal Drugs Market Forecast, by End-Users
16.17.1. Hospital Pharmacies
16.17.2. Retail Pharmacies
16.17.3. Online Pharmacies
16.18. Mexico Gastrointestinal Drugs Market Forecast, by Drug Category
16.18.1. Acid Neutralizers
16.18.1.1. Antacids
16.18.1.2. H2 Antagonists
16.18.1.3. Proton Pump Inhibitors
16.18.2. Helicobacter Pylori Eradication
16.18.3. Laxatives and Anti-diarrheal
16.18.4. Antiemetic and Antinauseants
16.18.5. Anti-inflammatory Drugs
16.18.6. Biologics
16.18.7. Others
16.19. Mexico Gastrointestinal Drugs Market Forecast, by Route of Administration
16.19.1. Oral
16.19.2. Parenteral
16.19.3. Rectal
16.20. Mexico Gastrointestinal Drugs Market Forecast, by Disease Type
16.20.1. Gastroesophageal Reflux Disorder
16.20.2. Irritable Bowel Syndrome
16.20.3. Others
16.21. Mexico Gastrointestinal Drugs Market Forecast, by End-Users
16.21.1. Hospital Pharmacies
16.21.2. Retail Pharmacies
16.21.3. Online Pharmacies
16.22. Rest of South America Gastrointestinal Drugs Market Forecast, by Drug Category
16.22.1. Acid Neutralizers
16.22.1.1. Antacids
16.22.1.2. H2 Antagonists
16.22.1.3. Proton Pump Inhibitors
16.22.2. Helicobacter Pylori Eradication
16.22.3. Laxatives and Anti-diarrheal
16.22.4. Antiemetic and Antinauseants
16.22.5. Anti-inflammatory Drugs
16.22.6. Biologics
16.22.7. Others
16.23. Rest of South America Gastrointestinal Drugs Market Forecast, by Route of Administration
16.23.1. Oral
16.23.2. Parenteral
16.23.3. Rectal
16.24. Rest of South America Gastrointestinal Drugs Market Forecast, by Disease Type
16.24.1. Gastroesophageal Reflux Disorder
16.24.2. Irritable Bowel Syndrome
16.24.3. Others
16.25. Rest of South America Gastrointestinal Drugs Market Forecast, by End-Users
16.25.1. Hospital Pharmacies
16.25.2. Retail Pharmacies
16.25.3. Online Pharmacies
16.26. South America Gastrointestinal Drugs Market Attractiveness Analysis
16.26.1. By Drug Category
16.26.2. By Route of Administration
16.26.3. By Disease Type
16.26.4. By End-Users
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments
17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. AbbVie Inc.
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Development Footprint
17.3.2. AstraZeneca
17.3.3. Johnson & Johnson
17.3.4. Abbott Laboratories
17.3.5. Allergan Plc
17.3.6. Bayer AG
17.3.7. Janssen Biotech Inc.
17.3.8. Takeda Pharmaceutical Company Limited
17.3.9. Eisai Co.Ltd.
17.3.10. Valeant Pharmaceuticals
17.3.11. Sanofi
17.3.12. Janssen Biotech
17.3.13. GlaxoSmithKline Plc
17.3.14. Boehringer Ingelheim GmbH
17.3.15. Novo Nordisk A/S
17.3.16. Teva
17.3.17. Zeria
17.3.18. Perrigo
17.3.19. Purdue Pharma
17.3.20. C.B. Fleet
18. Primary Key Insights